Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Medshine Discovery Inc.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Luoxin Pharmaceutical (shanghai) Co., Ltd.

North China Pharmaceutical New Drug R&d Co., Ltd.

North China Pharmaceutical Company., Ltd.

China Resources Biopharmaceutical Company Limited

Luoxin Pharmaceutical Co., Ltd.

Xiaobing Yan

Shuhui Chen

Wei Huang

Charles Z Ding

Jian Li

Xiquan Zhang

Guoping Hu

Zhaozhong Ding

Ting Wang

Chengde Wu

Kevin X Chen

Feng Guo

Hongjiang Xu

Ling Yang

Tie-Lin Wang

Dan Li

Fei Liu

Jiaqiang Dong

Yaxian Cai

Gangli Gong

Baoling Duan

Renlong Gao

Pingfan Zhou

Xinhua Lu

Guimin Dong

Guanghua Lai

Yuekun Nie

Jianglei Huang

Disclosed are a class of macrocyclic derivatives, a preparation method therefor, a pharmaceutical composition containing the derivatives, and the use thereof as therapeutic agents, particularly as XIa factor inhibitors and in the preparation of a drug for treating and preventing thromboembolisms and other diseases. Particularly disclosed are compounds shown by formula (I), an isomer thereof and a pharmaceutically acceptable salt thereof.

Macrocyclic derivatives acting as XIa factor inhibitor

Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof. 

Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors

Provided are a crystal and salt of an m-dihydroxybenzene derivative represented by formula (I), a manufacturing method thereof, and an application of the crystal in preparing a pharmaceutical product for treating a HSP90-mediated disease. 

M-dihydroxybenzene derivative crystal and salt, and manufacturing method thereof

A preparation method for a high-purity benzoxazoleoxazine ketone compound, a crystal form thereof, and an intermediate compound for preparing a compound of formula (I), and a preparation method therefor. 

Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds. 

Resorcinol derivative as HSP90 inhibitor

Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is selected from a 3-9 membered carbon ring or a ring which is formed by 3-9 membered carbocyclic ring fused with benzo ring, and a 4-10 membered heterocyclic ring or a ring which is formed by 4-10 membered heterocyclic ring fused with benzo ring; Y and Z are independently selected from 4-9 membered saturated heterocyclic rings respectively; Rare independently selected from H, F, Cl, Br, I, CN, OH, SH, NH, CHO, COOH respectively, or selected from the group, optionally substituted by R, consisting of Calkyl, Cheteroalkyl, Ccyclohydrocarbyl, Cheterocyclohydrocarbyl, Calkyl substituted by Ccyclohydrocarbyl or Cheterocyclohydrocarbyl, and Cheteroalkyl substituted by Ccyclohydrocarbyl or Cheterocyclohydrocarbyl. The compound can be used as an anticoagulant for treating and preventing thrombotic disorders, and can meet the real needs of selectivity and a potent inhibitor for coagulation Xa. 

Hydrazine compound as blood coagulation factor Xa inhibitor

Growing community of inventors

Shanghai, China

Xiaobing Yan